Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C.

ChemMedChem - 19 May 2020

Mortier Jérémie, Friberg Anders, Badock Volker, Moosmayer Dieter, Schroeder Jens, Steigemann Patrick, Siegel Franziska, Gradl Stefan, Bauser Marcus, Hillig Roman C, Briem Hans, Eis Knut, Bader Benjamin, Nguyen Duy, Christ Clara D

Abstract excerpt

Due to its frequent mutations in multiple lethal cancers, KRAS is one of the most-studied anticancer targets nowadays. Since the discovery of the druggable allosteric binding site containing a G12C mutation, KRASG12C has been the focus of attention in oncology research. We report here a computationally driven approach aimed at identifying novel and selective KRASG12C covalent inhibitors. The workflow involved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Molecular Structure

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 32237114
DOI: 10.1002/cmdc.201900727
PMCID: PMC7318243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C.PMID 32237114Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.Semantic proximity Read ↗

CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.Semantic proximity Read ↗

KRAS G12D can be targeted by potent salt-bridge forming inhibitorsSemantic proximity Read ↗

Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector bindingSemantic proximity Read ↗

Identification of KRAS mutants (G12C, G12D, and G12V) inhibitors.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

KRAS Binders Hidden in NatureSemantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

Structure-Based Virtual Screening for Novel Inhibitors Targeting KRAS G12C.Semantic proximity Read ↗

Analysis of KRAS-Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.